Skip to main content
$7.72Today:- (-)1Y −25.82%

As of Oct 16, 2026 close

Market cap
$206.85M
P/E (TTM)
-
Forward P/E
-
Dividend yield
-
52-week range
$2.59$12.23
Volume (live)
-
Avg. volume (3M)
325.81K

Exagen (XGN) Cash Flow Statement

In fiscal 2025 (fiscal year ended Dec 31, 2025), Exagen used $13.63M of cash in operating activities and spent $641.00K on capital expenditures. That left free cash flow of −$14.27M.

Exagen Cash Flow Statement Analysis

Values in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for Exagen Inc. (XGN) - Annual data in millions USD
BreakdownFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017
Period endingDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017
Operating Activities
Net Income-19.95-15.12-23.69-47.39-26.85-16.69-12.04-8.01-25.63
Depreciation & Amortization2.121.722.171.560.950.550.590.730.67
Deferred Income Tax0.000.000.00-0.310.15-0.11-0.250.03-0.55
Stock Based Compensation2.161.763.624.704.732.690.570.110.19
Change in Working Capital-1.98-3.080.331.67-0.06-1.340.17-3.59-2.02
Change in Accounts Receivable-3.02-1.28-0.473.58-0.74-3.200.24-2.26-0.20
Change in Inventory0.000.000.000.000.000.00-0.57-0.500.44
Change in Accounts Payable0.040.310.070.90-0.660.990.53-0.820.04
Change in Other Working Capital0.801.43-1.77-2.811.340.87-0.02-0.01-2.30
Other Operating Activities4.031.433.127.620.820.811.241.4316.38
Net Cash from Operating Activities-13.63-13.28-14.46-32.14-20.27-14.08-9.71-9.30-10.97
Investing Activities
Capital Expenditures-0.64-0.52-0.83-4.32-2.37-0.46-0.40-0.20-0.57
Acquisitions0.020.000.000.000.000.000.300.000.06
Purchases of Investments0.000.000.000.000.000.000.00-2.000.00
Sales/Maturities of Investments0.000.000.000.000.000.000.002.000.00
Other Investing Activities0.000.000.020.00-0.050.000.000.000.06
Net Cash from Investing Activities-0.63-0.52-0.80-4.32-2.42-0.46-0.10-0.20-0.51
Financing Activities
Debt Repayment-20.30-0.86-10.24-0.70-0.53-0.25-0.144.964.51
Common Stock Issued22.420.200.310.4569.140.1750.452.7214.64
Dividends Paid0.000.000.000.000.000.00-6.740.000.00
Other Financing Activities-0.87-0.49-0.70-0.24-3.94-0.0225.1712.9325.52
Net Cash from Financing Activities24.44-0.66-10.63-0.4964.68-0.1068.7311.4219.16
Summary
Net Change in Cash10.18-14.46-25.90-36.9541.99-14.6458.921.927.68
Cash at Beginning of Period22.2436.6962.5999.5457.5572.1813.2611.343.66
Cash at End of Period32.4222.2436.6962.5999.5457.5572.1813.2611.34
Free Cash Flow-14.27-13.79-15.29-36.46-22.64-14.54-10.11-9.50-11.54
Supplemental Disclosures
Interest Paid-1.721.741.731.821.76---

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About Exagen Cash Flow

What is Exagen's free cash flow?

Exagen had negative free cash flow of $14.27M in fiscal 2025 (fiscal year ended Dec 31, 2025), operating cash flow of −$13.63M minus $641.00K of capital expenditures.

How much does Exagen spend on capital expenditures?

Exagen spent $641.00K on capital expenditures in fiscal 2025, compared with $515.00K a year earlier.

Does Exagen pay dividends or buy back shares?

Exagen's cash flow statement for fiscal 2025 shows no dividend payments or share repurchases.

What is free cash flow?

Free cash flow is operating cash flow minus capital expenditures. It is the cash a company has left for dividends, buybacks, debt repayment or acquisitions after funding its operations and investment. Full definition